Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world.
Alvogen has commercial operations in 35 countries with 2,600 employees and operates five manufacturing and development hubs in the US, Romania, Korea and Taiwan. North America is Alvogen’s single largest market, other key markets include: South Korea, West Balkan, Poland, Romania, Bulgaria, Hungary, Taiwan, Thailand, Ukraine, Russia, Japan and China.
Alvogen has built a solid growth platform across the CEE region. Central & Eastern Europe therefore represents a strong platform for growth, with excellent manufacturing facilities in Romania and a packaging centre in Serbia serving the entire region.
The group has enjoyed successful product launches in all markets and has the potential to catalyze growth even further in countries such as Russia, the Commonwealth of Independent States (CIS) and the Balkan region.